Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 18

1.

A phase 2 trial of dasatinib in advanced melanoma.

Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, Molinaro A, Sznol M.

Cancer. 2011 May 15;117(10):2202-8. doi: 10.1002/cncr.25766. Epub 2010 Nov 29.

2.

Dasatinib: an anti-tumour agent via Src inhibition.

Gnoni A, Marech I, Silvestris N, Vacca A, Lorusso V.

Curr Drug Targets. 2011 Apr;12(4):563-78. Review.

PMID:
21226671
3.

Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.

Montero JC, Seoane S, Ocaña A, Pandiella A.

Clin Cancer Res. 2011 Sep 1;17(17):5546-52. doi: 10.1158/1078-0432.CCR-10-2616. Epub 2011 Jun 13. Review.

5.
6.

Upcoming strategies for the treatment of metastatic melanoma.

Spagnolo F, Queirolo P.

Arch Dermatol Res. 2012 Apr;304(3):177-84. doi: 10.1007/s00403-012-1223-7. Epub 2012 Feb 17. Review.

PMID:
22350184
7.

New approved dasatinib regimen available for clinical use.

Snyder DS.

Expert Rev Anticancer Ther. 2009 Mar;9(3):285-92. doi: 10.1586/14737140.9.3.285. Review.

PMID:
19275507
8.
9.

Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.

Satzger I, Küttler U, Völker B, Schenck F, Kapp A, Gutzmer R.

Dermatology. 2010;220(1):77-81. doi: 10.1159/000265558. Epub 2009 Dec 9. Review.

10.

Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.

Pavey T, Hoyle M, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, Garside R, Anderson R.

Health Technol Assess. 2012;16(42):iii-iv, 1-277. doi: 10.3310/hta16420. Review.

11.

Vemurafenib: in unresectable or metastatic melanoma.

Keating GM.

BioDrugs. 2012 Oct 1;26(5):325-34. doi: 10.2165/11209860-000000000-00000. Review.

PMID:
22946753
12.

Dasatinib: is it all in the dose?

Condorelli F, Genazzani AA.

BioDrugs. 2010 Jun;24(3):157-63. doi: 10.2165/11535870-000000000-00000. Review.

PMID:
20222756
13.

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.

Wei G, Rafiyath S, Liu D.

J Hematol Oncol. 2010 Nov 26;3:47. doi: 10.1186/1756-8722-3-47. Review.

14.

Therapeutic implications of KIT in melanoma.

Postow MA, Carvajal RD.

Cancer J. 2012 Mar-Apr;18(2):137-41. doi: 10.1097/PPO.0b013e31824b2404. Review.

PMID:
22453014
15.

Dasatinib in solid tumors.

Kim LC, Rix U, Haura EB.

Expert Opin Investig Drugs. 2010 Mar;19(3):415-25. doi: 10.1517/13543781003592097. Review.

PMID:
20113198
16.

The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients.

Kruser TJ, Traynor AM, Wheeler DL.

Expert Opin Investig Drugs. 2011 Feb;20(2):305-7. doi: 10.1517/13543784.2011.550873. Epub 2011 Jan 5. Review.

17.

Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.

Woodman SE, Davies MA.

Biochem Pharmacol. 2010 Sep 1;80(5):568-74. doi: 10.1016/j.bcp.2010.04.032. Epub 2010 May 8. Review.

18.

Masitinib for the treatment of mild to moderate Alzheimer's disease.

Folch J, Petrov D, Ettcheto M, Pedrós I, Abad S, Beas-Zarate C, Lazarowski A, Marin M, Olloquequi J, Auladell C, Camins A.

Expert Rev Neurother. 2015 Jun;15(6):587-96. doi: 10.1586/14737175.2015.1045419. Epub 2015 May 11. Review.

PMID:
25961655
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk